Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab for Relapsed/Refractory Germ Cell Tumors
NCT03158064Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2017
- Primary completion
- Nov 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in germ cell tumor (GCT), sponsored by Memorial Sloan Kettering Cancer Center. Started May 2017; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT03158064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03158064.